Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Kissei Pharmaceutical Co ( (JP:4547) ).
Kissei Pharmaceutical Co., Ltd. has submitted a new drug application in Japan for Linzagolix, a GnRH antagonist aimed at treating uterine fibroids. The drug has shown promising results in clinical trials and is already being launched in Europe by licensee Theramex. This development is part of Kissei’s broader strategy to expand its market presence and provide effective treatments for women’s health issues globally.
More about Kissei Pharmaceutical Co
Kissei Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development and marketing of drugs. The company is headquartered in Matsumoto, Nagano, Japan, and is involved in the creation of treatments for conditions such as uterine fibroids and endometriosis.
YTD Price Performance: -9.27%
Average Trading Volume: 750
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.01B
See more data about 4547 stock on TipRanks’ Stock Analysis page.